title: When a thymic carcinoma "becomes" a GIST.
abstract: Thymic carcinoma (TC) is a rare intrathoracic malignancy that it can be invasive and refractory to conventional treatment. Comprehensive genomic analysis evidenced a molecularly distinct subset of thymic carcinoma with high prevalence of c-kit mutation, which may behave as a gastrointestinal stromal tumor (GIST). Here, we present a case report of TC with c-Kit mutation, who has relapsed after exposure to multiple lines of combination chemotherapy, but he has shown an impressive and long lasting response to sunitinib after imatinib failure.
authors: Department of Medical Oncology, Istituti Ospitalieri of Cremona, Italy. valentina.rossi@ircc.it
authors: Valentina
authors: V
authors: Rossi
authors: Maddalena
authors: M
authors: Donini
authors: Pietro
authors: P
authors: Sergio
authors: Rodolfo
authors: R
authors: Passalacqua
authors: Giulio
authors: G
authors: Rossi
authors: Sebastiano
authors: S
authors: Buti
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D013945:Thymoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib